Prediction Value of BRCA1 for Platinum-based Chemotherapies Effect on Advanced Non-small Cell Lung Cancer Patients: A Meta-analysis
-
摘要:目的
运用Meta分析BRCA1表达与晚期非小细胞肺癌患者经铂类化疗后疗效之间的关系，探索BRCA1基因表达能否预测铂类化疗的疗效。
方法计算机检索PubMed、CNKI和万方中文数据库，按照制订的纳入与排除标准筛选关于BRCA1表达预测非小细胞肺癌铂类化疗后获益相关的临床研究，检索时限为数据库建库至2015年7月。获得所需的数据，使用RevMan5.4.1进行统计分析。
结果共纳入相关研究19项。Meta分析结果：BRCA1表达阳性患者与阴性患者的铂类化疗疗效无明显差异，合并比值比为0.80（95%e: 0.54~1.17）。黄种人亚组的BRCA1阴性表达与晚期NSCLC患者铂类化疗敏感度正相关。对检测方法的亚组分析显示：用免疫组织化学、PCR法检测BRCA1表达水平与晚期NSCLC患者铂类药物化疗敏感度无关。BRCA1与晚期NSCLC患者铂类PFS、OS获益并不相关。
结论本组研究异质性较大，BRCA1表达与NSCLC患者对铂类药物化疗后疗效的关系仍应开展更多大样本随机对照试验加以验证。
Abstract:ObjectiveTo evaluate the prediction value of BRCA1 for platinum-based chemotherapies effect on advanced non-small cell lung cancer(NSCLC) patients.
MethodsPubMed, CNKI and Wanfang database were all searched using a computer to collect clinical studies in accordance with the established inclusion and exclusion criteria regarding BRCA1 expression predicted the benefit from platinum-based chemotherapy on NSCLC. The deadline was July 2015. A RevMan 5.4.1 software was used for statistical analysis.
ResultsA total of 19 case-control studies were included in the Meta-analysis. The results showed no associations between BRCA1 expression and the clinical outcomes of platinum-based chemotherapies on advanced NSCLC patients. The pooled OR was 0.80 (95%e: 0.54-1.17). The subgroup analysis based on ethnicity showed negative BRCA1 expression was in favor of better overall response rate (ORR) in the Asian.The subgroup analysis of the detection method showed BRCA1 expression levels detected by IHC or PCR had no correlation with the sensitivity to platinum-based chemotherapy on patients with advanced NSCLC. BRCA1 was not associated with PFS or OS benefit in advanced NSCLC patients.
ConclusionThere is no association between BRCA1 expression and the clinical outcomes of platinum-based chemotherapies on advanced NSCLC patients; however, further studies are needed to validate the conclusion.
-
Key words:
- Non-small cell lung cancer /
- BRCA1 /
- Platinum-based chemotherapy
-
-
![]()
图 1 筛选BRCA1与铂类药物化疗疗效相关文献的流程图
Figure 1 The flow chart of relevant literature selection on BRCA1 and platinum chemotherapy efficacy
![]()
图 3 BRCA1与铂类化疗疗效人种亚组分析
Figure 3 Ethnic subgroup analysis of BRCA1 and platinum chemotherapy efficacy
![]()
图 5 晚期NSCLC患者BRCA1表达水平与铂类化疗PFS获益的Meta分析
Figure 5 Meta-analysis of BRCA1 expression levels in advanced NSCLC patients and PFS benefit from platinum-based chemotherapy
![]()
图 6 晚期NSCLC患者BRCA1表达水平与铂类化疗OS获益的Meta分析
Figure 6 Meta-analysis of BRCA1 expression levels in advanced NSCLC patients and OS benefit from platinum-based chemotherapy
表 1 纳入BRCA1与铂类化疗疗效相关研究的一般信息
Table 1 The basic characteristics of included studies on BRCA1 and platinum chemotherapy efficacy
下载: 导出CSV
-
[1] Mowls DS, Campbell J, Beebe LA. Race and Gender Disparities in Lung Cancer Incidence Rates, 2001-2010[J]. J Okla State Med Assoc, 2015, 108(11): 482-7. [1] Mowls DS, Campbell J, Beebe LA. Race and Gender Disparities in Lung Cancer Incidence Rates, 2001-2010[J]. J Okla State Med Assoc, 2015, 108(11): 482-7. http://cn.bing.com/academic/profile?id=2303543932&encoded=0&v=paper_preview&mkt=zh-cn
[2] Liang JG, Jin ZY, Gao XD, et al. Predictive role of RRM1 and BRCA1 mRNA expression on the clinical outcome of advanced non-small cell lung cancer[J]. Genet Mol Res, 2014, 13(3): 5292-8. doi: 10.4238/2014.July.24.8
[2] Liang JG, Jin ZY, Gao XD, et al. Predictive role of RRM1 and BRCA1 mRNA expression on the clinical outcome of advanced non-small cell lung cancer[J]. Genet Mol Res, 2014, 13(3): 52 92-8. [3] Vaclová T, Gómez-López G, Setién F, et al. DNA repair capacity is impaired in healthy BRCA1 heterozygous mutation carriers[J]. Breast Cancer Res Treat, 2015, 152(2): 271-82. [3] Vaclová T, Gómez-López G, Setién F, et al. DNA repair capacity is impaired in healthy BRCA1 heterozygous mutation carriers[J]. Breast Cancer Res Treat, 2015, 152(2): 271-82. doi: 10.1007/s10549-015-3459-3
[4] 阮芳芳, 姜维美. BRCA1、TUBB3在晚期非小细胞肺癌中的表 达及与铂类疗效的关系[J]. 实用医学杂志, 2014, 30(5): 732-4. [Ruan FF, Jiang WM. Relationship between the expression of BRCA1 and TUBB3 in patients with advanced non-small-cell lung cancer and its efficacy to platinum-based chemotherapy[J]. Shi Yong Yi Xue Za Zhi, 2014, 30(5): 732-4.] [4] 阮芳芳, 姜维美. BRCA1、TUBB3在晚期非小细胞肺癌中的表达及与铂类疗效的关系[J]. 实用医学杂志, 2014, 30(5): 732-4. http://www.cnki.com.cn/Article/CJFDTOTAL-SYYZ201405020.htm Ruan FF, Jiang WM. Relationship between the expression of BRCA1 and TUBB3 in patients with advanced non-small-cell lung cancer and its efficacy to platinum-based chemotherapy[J].Shi Yong Yi Xue Za Zhi, 2014, 30(5): 732-4. http://www.cnki.com.cn/Article/CJFDTOTAL-SYYZ201405020.htm
[5] 赵光日, 周明, 戴璐, 等. DNA修复相关基因ERCC1、BRCA1在 非小细胞肺癌化疗耐药中的作用研究[J]. 广西医学, 2014(6): 71 3-4. [Zhao GR, Zhou M, Dai L, et al. Role of DNA Repair -Related Genes ERCC1, BRCC1 in Chemotherapy Resistance of Non-Small Cell Lung Cancer[J]. Guangxi Yi Xue, 2014(6): 71 3-4.] [5] 赵光日, 周明, 戴璐, 等. DNA修复相关基因ERCC1、BRCA1在非小细胞肺癌化疗耐药中的作用研究[J]. 广西医学, 2014(6): 713-4. http://www.cnki.com.cn/Article/CJFDTOTAL-GYYX201406006.htm Zhao GR, Zhou M, Dai L, et al. Role of DNA Repair -Related Genes ERCC1, BRCC1 in Chemotherapy Resistance of Non-Small Cell Lung Cancer[J]. Guangxi Yi Xue, 2014(6): 713-4. http://www.cnki.com.cn/Article/CJFDTOTAL-GYYX201406006.htm
[6] Pierceall WE, Olaussen KA, Rousseau V, et al. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses[J]. Ann Oncol, 2012, 23(9): 2245-52. doi: 10.1093/annonc/mdr624
[6] Pierceall WE, Olaussen KA, Rousseau V, et al. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses[J]. Ann Oncol, 2012, 23(9): 2245-52. [7] Leng XF, Chen MW, Xian L, et al. Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy[J]. J Exp Clin Cancer Res, 2012, 31: 25. doi: 10.1186/1756-9966-31-25
[7] Leng XF, Chen MW, Xian L, et al. Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy[J]. J Exp Clin Cancer Res, 2012, 31 : 25. [8] Zhang Y, Yang H, Qiu Y, et al. Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer[J]. Med Oncol, 2014, 31(3): 803. [8] Zhang Y, Yang H, Qiu Y, et al. Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer[J]. Med Oncol, 2014, 31(3): 803. doi: 10.1007/s12032-013-0803-5
[9] Papadaki C, Tsaroucha E, Kaklamanis L, et al. Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer[J]. Br J Cancer, 2011, 104(2): 316-23. doi: 10.1038/sj.bjc.6606027
[9] Papadaki C, Tsaroucha E, Kaklamanis L, et al. Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer[J]. Br J Cancer, 2011, 104(2): 316-23. [10] Boukovinas I, Papadaki C, Mendez P, et al. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients[J]. PLoS One, 2008, 3(11): e3695. http://cn.bing.com/academic/profile?id=2008191260&encoded=0&v=paper_preview&mkt=zh-cn
[10] Boukovinas I, Papadaki C, Mendez P, et al. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical responseto first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients[J]. PLoS One, 2008, 3(11): e3695. [11] Santarpia M, Magri I, Sanchez-Ronco M, et al. mRNA expression levels and genetic status of genes involved in the EGFR and NF-kappaB pathways in metastatic non-small-cell lung cancer patients[J]. J Transl Med, 2011, 9: 163. [11] Santarpia M, Magri I, Sanchez-Ronco M, et al. mRNA expression levels and genetic status of genes involved in the EGFR and NF-kappaB pathways in metastatic non-small-cell lung cancer patients[J]. J Transl Med, 2011, 9: 163. doi: 10.1186/1479-5876-9-163
[12] Taron M, Rosell R, Felip E, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer[J]. Hum Mol Genet, 2004, 13(20): 2443-9. doi: 10.1093/hmg/ddh260
[12] Taron M, Rosell R, Felip E, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer[J]. Hum Mol Genet, 2004, 13(20): 2443-9. [13] Rosell R, Perez-Roca L, Sanchez JJ, et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression[J]. PLoS One, 2009, 4(5): e5133. doi: 10.1371/journal.pone.0005133
[13] Rosell R, Perez-Roca L, Sanchez JJ, et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression[J]. PLoS One, 2009, 4(5): e5133. [14] 鲁小敏, 茅国新, 吉浩明. BRCA1在非小细胞肺癌中的表达及 其与铂类化疗敏感性的关系[J]. 实用医学杂志, 2010, 26(19): 35 26-8. [Lu XM, Mao GX, Ji HM. BRCA1 expression levels and clinical response to platinum in non-small cell lung cancer[J]. Shi Yong Yi Xue Za Zhi, 2010, 26(19): 3526-8.] [14] 鲁小敏, 茅国新, 吉浩明. BRCA1在非小细胞肺癌中的表达及其与铂类化疗敏感性的关系[J]. 实用医学杂志, 2010, 26(19): 3526-8. http://www.cnki.com.cn/Article/CJFDTOTAL-SYYZ201019027.htm Lu XM, Mao GX, Ji HM. BRCA1 expression levels and clinical response to platinum in non-small cell lung cancer[J]. Shi Yong Yi Xue Za Zhi, 2010, 26(19): 3526-8. http://www.cnki.com.cn/Article/CJFDTOTAL-SYYZ201019027.htm
[15] 莫汉文, 李丽萍, 刘琦, 等. ERCC1、BRCA1、RRM1表达与含 铂类方案治疗晚期NSCLC的关系研究[J]. 中国临床研究, 2011, 24 (4): 283-4. [Mo HW, Li LP, Liu L, et al. ERCC1, BRCA1, RRM1 expression and platinum sensitivity among advanced nonsmall cell lung cancer patients[J]. Zhongguo Lin Chuang Yan Jiu, 20 11, 24(4): 283-4.] [15] 莫汉文, 李丽萍, 刘琦, 等. ERCC1、BRCA1、RRM1表达与含铂类方案治疗晚期NSCLC的关系研究[J]. 中国临床研究, 2011, 24(4): 283-4. http://www.cnki.com.cn/Article/CJFDTOTAL-ZGCK201104011.htm Mo HW, Li LP, Liu L, et al. ERCC1, BRCA1, RRM1 expression and platinum sensitivity among advanced non-small cell lung cancer patients[J]. Zhongguo Lin Chuang Yan Jiu, 2011, 24(4): 283-4. http://www.cnki.com.cn/Article/CJFDTOTAL-ZGCK201104011.htm
[16] 刘婷. ERCC1、BRCA1、EGFR、β-tubulin、K-Ras蛋白表达与 晚期非小细胞肺癌化疗疗效及预后的关系[D]. 乌鲁木齐：新 疆医科大学, 2010. [Liu T. The relationship between the protein expression of ERCC1, BRCA1, EGFR, β-tubulin and K-Ras and the efficacy and prognosis in advanced non-small cell lung cancer[D]. Urumqi: Xinjiang yi ke da xue, 2010.] [16] 刘婷. ERCC1、BRCA1、EGFR、β-tubulin、K-Ras蛋白表达与晚期非小细胞肺癌化疗疗效及预后的关系[D]. 乌鲁木齐：新疆医科大学, 2010. Liu T. The relationship between the protein expression of ERCC1, BRCA1, EGFR, β-tubulin and K-Ras and the efficacy and prognosis in advanced non-small cell lung cancer[D]. Urumqi: Xinjiang yi ke da xue, 2010.
[17] 杨俊泉, 汪宏斌, 刘宏侠, 等. BRCA1 mRNA在非小细胞肺癌中 的表达及预后意义[J]. 中国热带医学, 2009, 9(9): 1705-7. [Yang JQ, Wang HB, Liu HX, et al. Expression of BRCA1 in non-small cell lung cancer and its significance in prognosis[J]. Zhongguo Re Dai Yi Xue, 2009, 9(9): 1705-7.] [17] 杨俊泉, 汪宏斌, 刘宏侠, 等. BRCA1 mRNA在非小细胞肺癌中的表达及预后意义[J]. 中国热带医学, 2009, 9(9): 1705-7. http://www.cnki.com.cn/Article/CJFDTOTAL-RDYX200909026.htm Yang JQ, Wang HB, Liu HX, et al. Expression of BRCA1 in non-small cell lung cancer and its significance in prognosis[J]. Zhongguo Re Dai Yi Xue, 2009, 9(9): 1705-7. http://www.cnki.com.cn/Article/CJFDTOTAL-RDYX200909026.htm
[18] 崔海靖, 窦珊珊, 张秀霞, 等. 晚期非小细胞肺癌组织中BRCA1、STMN1、RRM1的表达及其临床意义[J]. 现代生物医学进展, 2013, 13(29): 5719-22. http://www.cnki.com.cn/Article/CJFDTOTAL-SWCX201329031.htm Cui HJ, Dou SS, Zhang XX, et al. BRCA1, STMN1, RRM1 Expression and its Clinical Significance in Advanced Non-Small Cell Lung Cancer Patients[J]. Xian Dai Sheng Wu Yi Xue Jin Zhan, 2013, 13(29): 5719-22. http://www.cnki.com.cn/Article/CJFDTOTAL-SWCX201329031.htm
[18] 崔海靖, 窦珊珊, 张秀霞, 等. 晚期非小细胞肺癌组织中 BRCA1、STMN1、RRM1的表达及其临床意义[J]. 现代 生物医学进展, 2013, 13(29): 5719-22. [Cui HJ, Dou SS, Zhang XX, et al. BRCA1, STMN1, RRM1 Expression and its Clinical Significance in Advanced Non-Small Cell Lung Cancer Patients[J]. Xian Dai Sheng Wu Yi Xue Jin Zhan, 2013, 13(29): 57 19-22.] [19] 邓双年. 晚期非小细胞肺癌BRCA1表达与顺铂化疗疗效关系 及预后分析[D]. 遵义: 遵义医学院, 2013. [Deng SN. Non small cell lung cancer in BRCA1 expression and platinum resistance and its relationship[D]. Zunyi: Zunyi Yi Xue Yuan, 2013.] [19] 邓双年. 晚期非小细胞肺癌BRCA1表达与顺铂化疗疗效关系及预后分析[D]. 遵义: 遵义医学院, 2013. http://cdmd.cnki.com.cn/article/cdmd-10661-1013263839.htm Deng SN. Non small cell lung cancer in BRCA1 expression and platinum resistance and its relationship[D]. Zunyi: Zunyi Yi Xue Yuan, 2013. http://cdmd.cnki.com.cn/article/cdmd-10661-1013263839.htm
[20] Zhao H, Zhang H, Du Y, et al. Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy[J]. Tumour Biol, 2014, 35(12): 12679-88. doi: 10.1007/s13277-014-2592-7
[20] Zhao H, Zhang H, Du Y, et al. Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy[J]. Tumour Biol, 2014, 35 (12): 12679-88. [21] Li Z, Qing Y, Guan W, et al. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced nonsmall cell lung cancer (NSCLC) receiving first-line platinumpaclitaxel chemotherapy[J]. Cancer Chemother Pharmacol, 2014, 74 (4): 777-86. [21] Li Z, Qing Y, Guan W, et al. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy[J]. Cancer Chemother Pharmacol, 2014, 74(4): 777-86. doi: 10.1007/s00280-014-2562-1
[22] Liang JG, Jin ZY, Gao XD, et al. Predictive role of RRM1 and BRCA1 mRNA expression on the clinical outcome of advanced non-small cell lung cancer[J]. Genet Mol Res, 2014, 13(3): 5292-8. doi: 10.4238/2014.July.24.8
[22] Liang JG, Jin ZY, Gao XD, et al. Predictive role of RRM1 and BRCA1 mRNA expression on the clinical outcome of advanced non-small cell lung cancer[J]. Genet Mol Res, 2014, 13(3): 52 92-8. [23] Feng XJ, Qin XG, Li Z, et al. ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy[J]. Pak J Med Sci, 2014, 30(3): 488-92. http://cn.bing.com/academic/profile?id=2417844323&encoded=0&v=paper_preview&mkt=zh-cn
[23] Feng XJ, Qin XG, Li Z, et al. ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy[J]. Pak J Med Sci, 20 14, 30(3): 488-92. [24] Wang TB, Zhang NL, Wang SH, et al. Expression of ERCC1 and BRCA1 predict the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy[J]. Genet Mol Res, 2014, 13(2): 3704-10. doi: 10.4238/2014.May.9.15
[24] Wang TB, Zhang NL, Wang SH, et al. Expression of ERCC1 and BRCA1 predict the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy[J]. Genet Mol Res, 2014, 13(2): 3704-10. [25] Su C, Zhou S, Zhang L, et al. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer[J]. Med Oncol, 2011, 28(4): 1411-7. [25] Su C, Zhou S, Zhang L, et al. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer[J]. Med Oncol, 2011, 28(4): 1411-7. doi: 10.1007/s12032-010-9553-9
[26] Wang L, Meng L, Wang XW, et al. Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy[J]. Tumour Biol, 2014, 35(3): 1899-906. doi: 10.1007/s13277-013-1255-4
[26] Wang L, Meng L, Wang XW, et al. Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy[J]. Tumour Biol, 2014, 35(3): 18 99-906. [27] Tiseo M, Bordi P, Bortesi B, et al. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin[J]. Br J Cancer, 2013, 108(8): 1695-703. doi: 10.1038/bjc.2013.127
[27] Tiseo M, Bordi P, Bortesi B, et al. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin[J]. Br J Cancer, 2013, 108(8): 1695-703. [28] Joerger M, Dejong D, Burylo A, et al. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinumgemcitabine chemotherapy[J]. Lung Cancer, 2011, 74(2): 310-7. [28] Joerger M, Dejong D, Burylo A, et al. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy[J]. Lung Cancer, 2011, 74(2): 310-7. doi: 10.1016/j.lungcan.2011.03.016
[29] Ota S, Ishii G, Goto K, et al. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy[J]. Lung Cancer, 2009, 64(1): 98-104. [29] Ota S, Ishii G, Goto K, et al. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy[J]. Lung Cancer, 2009, 64(1): 98-104. doi: 10.1016/j.lungcan.2008.07.014
[30] Qin X, Yao W, Li W, et al. ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy[J]. Tumour Biol, 2014, 35(5): 4697-704. doi: 10.1007/s13277-014-1615-8
[30] Qin X, Yao W, Li W, et al. ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy[J]. Tumour Biol, 2014, 35(5): 4697-704. [31] Yang Y, Xie Y, Xian L. Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysis[J]. J Exp Clin Cancer Res, 2013, 32: 15. doi: 10.1186/1756-9966-32-15
[31] Yang Y, Xie Y, Xian L. Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysis[J]. J Exp Clin Cancer Res, 2013, 32 : 15. [32] 谷海燕, 项锋钢, 信芳杰, 等. NSCLC含铂新辅助化疗后ERCC1和BRCA1表达及其与疗效关系[J]. 齐鲁医学杂志, 2012, 27(2): 98-100. http://www.cnki.com.cn/Article/CJFDTOTAL-SPAN201202003.htm Gu QY, Xiang FG, Xin FJ, et al. Expressions of ERCC1 and BRCA1 and their relationship with curative effection in non small cell lung cancer after platinum-based neoadjuvant chemotherapy[J]. Qilu Yi Xue Za Zhi, 2012, 27(2): 98-100. http://www.cnki.com.cn/Article/CJFDTOTAL-SPAN201202003.htm
[32] 谷海燕, 项锋钢, 信芳杰, 等. NSCLC含铂新辅助化疗后ERCC1 和BRCA1表达及其与疗效关系[J]. 齐鲁医学杂志, 2012, 27(2): 98 -100. [Gu QY, Xiang FG, Xin FJ, et al. Expressions of ERCC1 and BRCA1 and their relationship with curative effection in non small cell lung cancer after platinum-based neoadjuvant chemotherapy[J]. Qilu Yi Xue Za Zhi, 2012, 27(2): 98-100.]
计量
- 文章访问数: 1212
- HTML全文浏览量: 323
- PDF下载量: 350
